| All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists L Carmona, MA Descalzo, E Perez-Pampin, D Ruiz-Montesinos, A Erra, ... Annals of the rheumatic diseases 66 (7), 880-885, 2007 | 288 | 2007 |
| Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial JV Perez-Moreiras, JJ Gomez-Reino, JR Maneiro, E Perez-Pampin, ... American Journal of Ophthalmology 195, 181-190, 2018 | 238 | 2018 |
| Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients J Loricera, R Blanco, JL Hernández, S Castañeda, A Mera, ... Seminars in arthritis and rheumatism 44 (6), 717-723, 2015 | 158 | 2015 |
| Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate MC de Andres, E Perez-Pampin, M Calaza, FJ Santaclara, I Ortea, ... Arthritis research & therapy 17, 1-9, 2015 | 138 | 2015 |
| Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis R Dieguez‐Gonzalez, M Calaza, E Perez‐Pampin, AR de la Serna, ... Arthritis & Rheumatism 58 (5), 1264-1274, 2008 | 118 | 2008 |
| Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice M Calderón-Goercke, J Loricera, V Aldasoro, S Castañeda, I Villa, ... Seminars in arthritis and rheumatism 49 (1), 126-135, 2019 | 115 | 2019 |
| Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility R Dieguez-Gonzalez, M Calaza, E Perez-Pampin, A Balsa, FJ Blanco, ... Arthritis research & therapy 11, 1-8, 2009 | 74 | 2009 |
| A CTLA‐4 polymorphism associated with susceptibility to systemic lupus erythematosus L Fernandez‐Blanco, E Perez‐Pampin, JJ Gomez‐Reino, A Gonzalez Arthritis & Rheumatism: Official Journal of the American College of …, 2004 | 66 | 2004 |
| Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors M Suarez‐Gestal, M Calaza, R Dieguez‐Gonzalez, E Perez‐Pampin, ... Arthritis & Rheumatism 60 (9), 2558-2564, 2009 | 64 | 2009 |
| Particular association of clinical and genetic features with autoimmunity to citrullinated α‐enolase in rheumatoid arthritis A Montes, R Dieguez‐Gonzalez, E Perez‐Pampin, M Calaza, ... Arthritis & Rheumatism 63 (3), 654-661, 2011 | 53 | 2011 |
| Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis R Dieguez-Gonzalez, S Akar, M Calaza, E Perez-Pampin, J Costas, ... Annals of the rheumatic diseases 68 (4), 579-583, 2009 | 51 | 2009 |
| Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0 L Carmona, MA Descalzo, D Ruiz-Montesinos, FJ Manero-Ruiz, ... Rheumatology 50 (1), 85-92, 2011 | 49 | 2011 |
| Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies A Montes, C Regueiro, E Perez-Pampin, MD Boveda, JJ Gomez-Reino, ... PloS one 11 (8), e0161141, 2016 | 48 | 2016 |
| Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study M Suarez-Gestal, E Perez-Pampin, M Calaza, JJ Gomez-Reino, ... Arthritis research & therapy 12, 1-6, 2010 | 47 | 2010 |
| Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis A Montes, E Perez-Pampin, J Narváez, JD Cañete, F Navarro-Sarabia, ... Pharmacogenetics and Genomics 24 (5), 238-245, 2014 | 45 | 2014 |
| DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists F Navarro-Sarabia, D Ruiz-Montesinos, B Hernandez, ... BMC Musculoskeletal Disorders 10, 1-7, 2009 | 43 | 2009 |
| Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis A Ferreiro-Iglesias, A Montes, E Perez-Pampin, JD Canete, E Raya, ... The pharmacogenomics journal 16 (2), 137-140, 2016 | 42 | 2016 |
| Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective … I García‐Doval, MV Hernández, F Vanaclocha, A Sellas, P de la Cueva, ... British Journal of Dermatology 176 (3), 643-649, 2017 | 40 | 2017 |
| Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature J Ruiz-Bañobre, E Pérez-Pampín, J García-González, ... Lung Cancer 108, 217-221, 2017 | 39 | 2017 |
| BIOBADASER and EMECAR Groups. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists L Carmona, MA Descalzo, E Perez-Pampin, D Ruiz-Montesinos, A Erra, ... Ann Rheum Dis 66 (7), 880-5, 2007 | 38 | 2007 |
Juan Gomez-ReinoUNIVERSITY OF SANTIAGO, USC and FUNDACION IDIS, HOSPITAL CLINICO UNIVERSITARIO, SANTIAGO, SPAINAdresse e-mail validée de sergas.es
